Technical Analysis for URGN - UroGen Pharma Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 2.27% | |
| Lower Bollinger Band Touch | Weakness | 2.27% | |
| Oversold Stochastic | Weakness | 2.27% | |
| Stochastic Buy Signal | Bullish | 4.93% | |
| NR7 | Range Contraction | 4.93% | |
| Lower Bollinger Band Walk | Weakness | 4.93% | |
| Inside Day | Range Contraction | 4.93% | |
| Lower Bollinger Band Touch | Weakness | 4.93% | |
| Oversold Stochastic | Weakness | 4.93% | |
| New 52 Week Closing Low | Bearish | 6.07% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 44 minutes ago |
| Up 2% | about 1 hour ago |
| Down 1% | about 2 hours ago |
| Rose Above Previous Day's High | about 3 hours ago |
| Up 1% | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 11/06/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Platform Technologies Bladder Cancer Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.7 |
| 52 Week Low | 10.6001 |
| Average Volume | 625,040 |
| 200-Day Moving Average | 14.59 |
| 50-Day Moving Average | 12.45 |
| 20-Day Moving Average | 12.03 |
| 10-Day Moving Average | 11.82 |
| Average True Range | 0.69 |
| RSI (14) | 41.18 |
| ADX | 19.05 |
| +DI | 20.42 |
| -DI | 21.22 |
| Chandelier Exit (Long, 3 ATRs) | 11.31 |
| Chandelier Exit (Short, 3 ATRs) | 12.68 |
| Upper Bollinger Bands | 13.01 |
| Lower Bollinger Band | 11.06 |
| Percent B (%b) | 0.2 |
| BandWidth | 16.18 |
| MACD Line | -0.33 |
| MACD Signal Line | -0.24 |
| MACD Histogram | -0.0852 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.38 | ||||
| Resistance 3 (R3) | 12.29 | 11.88 | 12.23 | ||
| Resistance 2 (R2) | 11.88 | 11.65 | 11.93 | 12.17 | |
| Resistance 1 (R1) | 11.67 | 11.50 | 11.78 | 11.76 | 12.12 |
| Pivot Point | 11.26 | 11.26 | 11.32 | 11.31 | 11.26 |
| Support 1 (S1) | 11.05 | 11.03 | 11.16 | 11.14 | 10.78 |
| Support 2 (S2) | 10.64 | 10.88 | 10.69 | 10.73 | |
| Support 3 (S3) | 10.43 | 10.64 | 10.68 | ||
| Support 4 (S4) | 10.52 |
